Literature DB >> 18297112

Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint.

M Lei1, R L Erikson.   

Abstract

We previously reported that polo-like kinase 1 (Plk1) depletion by lentivirus-based RNA interference led to mitotic arrest and apoptosis in cancer cells, whereas normal diploid cell lines, hTERT-RPE1 and MCF10A, survived a similar level of depletion. To study homogeneous cell lines, we generated several Plk1-depleted hTERT-RPE1 and MCF10A clones that were derived from single cells depleted of Plk1. We found that in the long term, Plk1 depletion slowed proliferation of hTERT-RPE1 cells, apparently due to attenuated progression through S phase. These cells had altered morphology and were elongated compared with control. In contrast, MCF10A clones with mild levels of depletion showed no obvious phenotype. They appeared to have normal proliferation rates with no cell-cycle arrest. However, one MCF10A clone, which was severely depleted of Plk1, although viable, showed sporadic G2/M arrest and apoptosis. This MCF10A clone and all the hTERT-RPE1 clones displayed evidence of DNA-damage checkpoint activation. These data further support the interpretation that cancer cell lines have a much greater requirement for Plk1 than normal nontransformed diploid cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297112     DOI: 10.1038/onc.2008.36

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Authors:  Juping Yuan; Mourad Sanhaji; Andrea Krämer; Wolfgang Reindl; Matthias Hofmann; Nina-Naomi Kreis; Brigitte Zimmer; Thorsten Berg; Klaus Strebhardt
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

2.  Suppression of topoisomerase IIalpha expression and function in human cells decreases chromosomal radiosensitivity.

Authors:  Samantha Y A Terry; Andrew C Riches; Peter E Bryant
Journal:  Mutat Res       Date:  2009-02-04       Impact factor: 2.433

3.  Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.

Authors:  Jie Lu; John S Kovach; Francis Johnson; Jeffrey Chiang; Richard Hodes; Russell Lonser; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

4.  Involvement of polo-like kinase 1 (Plk1) in mitotic arrest by inhibition of mitogen-activated protein kinase-extracellular signal-regulated kinase-ribosomal S6 kinase 1 (MEK-ERK-RSK1) cascade.

Authors:  Ran Li; Dian-Fu Chen; Rong Zhou; Sheng-Nan Jia; Jin-Shu Yang; James S Clegg; Wei-Jun Yang
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

5.  Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress.

Authors:  Bing Song; X Shawn Liu; Korbin Davis; Xiaoqi Liu
Journal:  Mol Cell Biol       Date:  2011-09-26       Impact factor: 4.272

6.  Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes.

Authors:  Minhong Shen; Yuqi Cai; Yuehong Yang; Xiaoyi Yan; Xiaoqi Liu; Tianhua Zhou
Journal:  Cell Res       Date:  2013-09-10       Impact factor: 25.617

7.  Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.

Authors:  Zhiguo Li; Jie Li; Pengpeng Bi; Ying Lu; Grant Burcham; Bennett D Elzey; Timothy Ratliff; Stephen F Konieczny; Nihal Ahmad; Shihuan Kuang; Xiaoqi Liu
Journal:  Mol Cell Biol       Date:  2014-07-21       Impact factor: 4.272

8.  Jade-1S phosphorylation induced by CK1α contributes to cell cycle progression.

Authors:  Lori Borgal; Markus M Rinschen; Claudia Dafinger; Valérie I Liebrecht; Hinrich Abken; Thomas Benzing; Bernhard Schermer
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

9.  Polo-like kinase 1 (PLK1)-dependent phosphorylation of methylenetetrahydrofolate reductase (MTHFR) regulates replication via histone methylation.

Authors:  Xueyan Li; Shanshan Nai; Yuehe Ding; Qizhi Geng; Bingtao Zhu; Kai Yu; Wei-Guo Zhu; Meng-Qiu Dong; Xiao-Dong Su; Xingzhi Xu; Jing Li
Journal:  Cell Cycle       Date:  2017-08-18       Impact factor: 4.534

10.  Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.

Authors:  Wei Chuen Mok; Shanthi Wasser; Theresa Tan; Seng Gee Lim
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.